Pro Medicus Limited (ASX:PME) Secures A$40M, 7-Year Contract with LucidHealth
Pro Medicus Limited (ASX:PME) signs a A$40M, 7-year contract with LucidHealth to implement its cloud-based Visage 7 platform.
Category: Healthcare
PainChek Limited (ASX:PCK) Releases Half Year Results
PainChek Limited (ASX:PCK) reports a 27% revenue increase in its half-year results, highlighting growth and expansion into the US market.
The Hydration Pharmaceuticals Company Limited (ASX:HPC) Reports FY2024 Financial Results
The Hydration Pharmaceuticals Company Limited (ASX:HPC) reports a 25.5% revenue decline in FY2024, asset divestiture, and a strategic focus on US growth.
Epsilon Healthcare (ASX:EPN) Reports 43% Revenue Growth and Significant Loss Reduction for 2023
Epsilon Healthcare (ASX:EPN) reports a 43% revenue increase and a 92% reduction in net loss for 2023, alongside entering Voluntary Administration.
ECS Botanics Holdings Ltd (ASX:ECS) Reports Half-Year Financial Results
ECS Botanics Holdings Ltd (ASX:ECS) reports a $1.98m net loss and strategic expansions in export markets and product offerings.
Neurotech International Ltd (ASX:NTI) Receives EMA Positive Opinion
Neurotech International Ltd (ASX:NTI) receives EMA positive opinion for NTI164 in Rett Syndrome, marking a key regulatory milestone.
Monash IVF Group Limited (ASX:MVF) Reports 5.5% Underlying NPAT Growth in 1H25
Monash IVF Group (ASX:MVF) reports 11.6% revenue growth and declares a 2.6c interim dividend for 1H25.
Pacific Smiles Group Limited (ASX:PSQ) Reports 10% Revenue Growth and 52% Underlying Profit Increase for H1
Pacific Smiles Group Limited (ASX:PSQ) reports a 10% revenue increase and a 52% rise in underlying profit for the half-year ended 31 December 2024, alongside a major ownership change.
Telix Pharmaceuticals Limited (ASX:TLX) FDA Accepts BLA for TLX250-CDx
Telix Pharmaceuticals (ASX:TLX) announces FDA acceptance of BLA for TLX250-CDx, targeting kidney cancer imaging with a planned U.S. launch in 2025.
OncoSil Medical Ltd (ASX:OSL) Delivers Key Milestones and Financial Growth in H1 2025
OncoSil Medical Ltd (ASX:OSL) achieves significant clinical and financial milestones, expanding its global presence and enhancing its financial position in H1 2025.